Related references
Note: Only part of the references are listed.Role of phosphodiesterases in the shaping of sub-plasma-membrane cAMP oscillations and pulsatile insulin secretion
Geng Tian et al.
JOURNAL OF CELL SCIENCE (2012)
Strategic combination therapy overcomes tyrosine kinase coactivation in adrenocortical carcinoma
Chi-Iou Lin et al.
SURGERY (2012)
A genetically engineered human pancreatic β cell line exhibiting glucose-inducible insulin secretion
Philippe Ravassard et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes
Dariush Mokhtari et al.
CLINICAL SCIENCE (2010)
Deletion of Pten in Pancreatic β-Cells Protects Against Deficient β-Cell Mass and Function in Mouse Models of Type 2 Diabetes
Linyuan Wang et al.
DIABETES (2010)
SHIP2 and its involvement in various diseases
Akira Suwa et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2010)
Plasma Adiponectin Levels Are Markedly Elevated in Imatinib-Treated Chronic Myeloid Leukemia (CML) Patients: A Mechanism for Improved Insulin Sensitivity in Type 2 Diabetic CML Patients?
Stephen Fitter et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
A Protein Tyrosine Kinase Inhibitor, Imatinib Mesylate (Gleevec), Improves Erectile and Vascular Function Secondary to a Reduction of Hyperglycemia in Diabetic Rats
Serap Gur et al.
JOURNAL OF SEXUAL MEDICINE (2010)
Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia
Stefania Mariani et al.
LEUKEMIA RESEARCH (2010)
Genetics, pathogenesis and clinical interventions in type 1 diabetes
Jeffrey A. Bluestone et al.
NATURE (2010)
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice
Nicole M Agostino et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2010)
Specific Tyrosine Phosphorylations Mediate Signal-Dependent Stimulation of SHIP2 Inositol Phosphatase Activity, while the SH2 Domain Confers an Inhibitory Effect To Maintain the Basal Activity
Nagendra K. Prasad et al.
BIOCHEMISTRY (2009)
Imatinib Mesylate Reduces Endoplasmic Reticulum Stress and Induces Remission of Diabetes in db/db Mice
Myoung Sook Han et al.
DIABETES (2009)
Lack of β-catenin in early life induces abnormal glucose homeostasis in mice
S. Dabernat et al.
DIABETOLOGIA (2009)
Stromal cell-derived factor-1 promotes survival of pancreatic beta cells by the stabilisation of beta-catenin and activation of transcription factor 7-like 2 (TCF7L2)
Z. Liu et al.
DIABETOLOGIA (2009)
Potential of Small Molecule Protein Tyrosine Kinase Inhibitors as Immunomodulators and Inhibitors of the Development of Diabetes
Peter J. Little et al.
THESCIENTIFICWORLDJOURNAL (2009)
Glucose-induced cyclic AMP oscillations regulate pulsatile insulin secretion
Oleg Dyachok et al.
CELL METABOLISM (2008)
Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet
Robert Hagerkvist et al.
CLINICAL SCIENCE (2008)
Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation
Zhengyu Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML)
Apostolos Tsapas et al.
LEUKEMIA RESEARCH (2008)
Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover
A. Koch et al.
ONCOGENE (2008)
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice
Cedric Louvet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Increasing GLP-1-induced β-cell proliferation by silencing the negative regulators of signaling cAMP response element modulator-α and DUSP14
Sonia Klinger et al.
DIABETES (2008)
Remission of diabetes while on sunitinib treatment for renal cell carcinoma
A. Templeton et al.
ANNALS OF ONCOLOGY (2008)
Inhibition of SH2-domain containing inositol phosphatase 2 (SHIP2) in insulin producing INS1E cells improves insulin signal transduction and induces proliferation
Rolf Grempler et al.
FEBS LETTERS (2007)
Regulation of β-cell mass and function by the Akt/protein kinase B signalling pathway
L. Elghazi et al.
DIABETES OBESITY & METABOLISM (2007)
The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias
Taira Maekawa et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2007)
Regulation of PTEN activity by its carboxyl-terminal autoinhibitory domain
Leticia Odriozola et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Abl functions as a negative regulator of Met-induced cell motility via phosphorylation of the adapter protein CrkII
Angel Cipres et al.
CELLULAR SIGNALLING (2007)
KinasePhos 2.0: a web server for identifying protein kinase-specific phosphorylation sites based on sequences and coupling patterns
Yung-Hao Wong et al.
NUCLEIC ACIDS RESEARCH (2007)
Amelioration of diabetes by imatinib mesylate (Gleevec®):: role of β-cell NF-κB activation and anti-apoptotic preconditioning
Robert Hagerkvist et al.
FASEB JOURNAL (2007)
Glucose and insulin synergistically activate phosphatidylinositol 3-kinase to trigger oscillations of phosphatidylinositol 3,4,5-trisphosphate in β-cells
Olof Idevall Hagren et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro
Robert Hagerkvist et al.
CELL BIOLOGY INTERNATIONAL (2006)
Sensing extracellular matrix: An update on discoidin domain receptor function
Wolfgang F. Vogel et al.
CELLULAR SIGNALLING (2006)
Phosphorylation of β-catenin by cyclic AMP-dependent protein kinase
S Taurin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Stem cell factor and its receptor c-Kit as targets for inflammatory diseases
L Reber et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Imatinib and regression of type 2 diabetes
D Veneri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Inhibition of endogenous SHIP2 ameliorates insulin resistance caused by chronic insulin treatment in 3T3-L1 adipocytes
T Sasaoka et al.
DIABETOLOGIA (2005)
Imatinib mesylate may improve fasting blood glucose in diabetic Ph plus chronic myelogenous leukemia patients responsive to treatment
M Breccia et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Molecular insights into insulin action and secretion
CJ Rhodes et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2002)
Induction of the IL-13 receptor α2-chain by IL-4 and IL-13 in human keratinocytes:: involvement of STAT6, ERK and p38 MAPK pathways
M David et al.
ONCOGENE (2001)
Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor
F Frasca et al.
ONCOGENE (2001)
The lipid phosphatase SHIP2 controls insulin sensitivity
S Clément et al.
NATURE (2001)
Phosphorylation of the PTEN tail regulates protein stability and function
F Vazquez et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
c-abl is involved in the association of p53 and trk A
A Brown et al.
ONCOGENE (2000)
Share Paper
